This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies.
Based on a technology developed by Broad Institute core member David Liu’s laboratory, the treatment is the first in a series of new medicines being tested to treat rare diseases by repairing patients’ particular genetic misspellings. s to be produced at scale, making them the standard of care for life-threatening rare genetic diseases.
Its applications include studying disease pathology to develop targeted therapeutics, visualising enzymes that can decompose plastics, and engineering solutions to antibiotic resistance, among many others. David Baker is listed as an inventor on many patents, focused on compositions and methods for treating particular diseases.
The $400,000 prize, to be shared among the four winners, recognizes their role in creating and advancing a technology that has reshaped how physicians treat leukemia, lymphoma, and multiple myeloma, and is now showing promise in treating autoimmune and infectious diseases. A single dose of the engineered cells wiped out signs of disease.
In 2020, the FDA halted Johnson & Johnson’s COVID-19 vaccine production at a contract manufacturing facility after discovering quality control issues. One notable success story is Moderna’s mRNA vaccine development for COVID-19, which benefited from early regulatory engagement and streamlined approval pathways.
This meant putting the fundamentals of mRNA production directly into the hands of local innovators — a dramatic departure from previous models that kept much of vaccine production within a small number of firms in high-income settings. mRNA Technology Transfer Programme Moves Into Phase 2.0, 2026–2030).
Merck’s ENFLONSIA Receives ACIP Endorsement for RSV Prevention in Infants, Marking a Major Milestone in Pediatric Infectious Disease Prevention U.S. The disease burden is disproportionately high among infants under 1 year of age, and even more so among premature infants or those with underlying heart or lung conditions.
According to Thomas Triomphe, Executive Vice President of Vaccines at Sanofi, the product has been administered to over 250,000 infants in real-world settings, backed by more than 40 studies demonstrating its effectiveness in preventing RSV lower respiratory tract disease.
Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. Even after microbiologists discovered the bacterium that causes the illness in 1882, it wasn’t until the 1920s that researchers were able to develop a vaccine for TB.
“Second Generation Oral Mpro Inhibitor for COVID-19 Treatment Proceeds in Phase 3 Study” Precision Vaccinations. Jump up to: a b “Coronavirus disease 2019 (COVID-19) emerging treatments” BMJ Best Practice US. . ^ Jump up to: a b c d e f Hackett DW (26 June 2023). Retrieved 27 December 2023. 15 (1): 81–118.
Ibtrozi has also shown the ability to help people whose cancer has spread to the brain, a leading cause of disease progression, the company said. In a research note on Wednesday, RBC Capital Markets analyst Leonid Timashev estimated peak yearly sales of the drug could reach nearly $640 million.
2025 [link] The coronavirus disease 2019 (COVID-19) pandemic crisis has been mitigated by worldwide efforts to develop vaccines and therapeutic drugs. However, there remains concern regarding public health and an unmet need for therapeutic options.
The same team also invented several other products that proved useful for treating battlefield injuries, including gamma globulins to inoculate soldiers against diseases and fibrin film to minimize bleeding during brain surgeries. Still, Cohn’s work ought to be iconic amongst those interested in scientific progress and metascience.
Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Now, Vor is reestablishing itself as an autoimmune disease company. says US won’t donate to global vaccine effort View all Events 07 JUL Webinar | 10 a.m.
The Strategy must address appropriately restructuring the Federal Governments response to the childhood chronic disease crisis, including by ending Federal practices that exacerbate the health crisis or unsuccessfully attempt to address it, and by adding powerful new solutions that will end childhood chronic disease.
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of diarrhoeal disease and death in children under five by licensing its Shigella vaccine candidate, altSonflex1-2-3 , to Bharat Biotech International Limited (BBIL).
“Overcoming pathways to enable mechanisms within the immune system to combat disease has already seen validation with some of the recently approved drugs in the short- and medium-term,” Galbraith explains. “This is encouraging and is likely to stimulate investment moving forward.”
On a conference call held Wednesday afternoon, Sarepta CEO Doug Ingram said that "failure to adapt" to recent setbacks "would risk our long-term viability as an organization and decrease the opportunity to bring the greatest benefit to the greatest number of patients living with rare disease." Please select at least one newsletter.
Amodei also imagines the ways AI could accelerate biological research and yield miraculous cures in the 21st century; everything from the prevention and treatment of nearly all infectious and inherited diseases to the elimination of most cancers. This essay focuses on how we might do both, specifically for the cell. Subscribe to Asimov Press.
Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Moderna COVID vaccine gets full approval for children The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., Kennedy Jr.
Spencer Platt via Getty Images The first marketed treatment for the insatiable hunger associated with Prader-Willi disease is selling more quickly than Wall Street analysts expected, an early, but encouraging sign of demand. The disease, which affects an estimated 10,000 to 20,000 people in the U.S.,
Innovations like gene therapies are providing hope for diseases that previously had no treatment options, while precision medicine such as cell therapy personalises treatments to fit each patients signature biological characteristics. The COVID-19 pandemic highlighted these issues on a global scale.
While vaccines, therapeutics, and preventive measures have significantly reduced the global burden of the disease, […] The post COVID-19 in 2025: Are Decentralized Clinical Trials the New Standard? The world continues to feel the ripple effects of the COVID-19 pandemic, even into 2025. appeared first on ProRelix Research.
In a filing with the Securities and Exchange Commission in March, Lexeo said it was seeking “ business development opportunities ” for its portfolio of Alzheimer’s disease treatments, one of which it has brought into the clinic. Earlier this year, it laid off 15% of its workforce.
For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. However, Dyadic has now sharpened its strategic focus on commercializing non-therapeutic proteins—input molecules that are crucial for downstream manufacturing and production processes in various industries. “We
has agreed to pay $10 billion to buy London-based Verona Pharma, scooping up a potential multibillion-dollar new drug to treat chronic obstructive pulmonary disease in a deal announced Wednesday. Alamy Merck & Co. The Food and Drug Administration approved Verona’s Ohtuvayre in June 2024 for maintenance treatment of COPD in adults.
Most Popular Deep Dive Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B
Klarman joined the Broad Institute Board of Directors when it was formed in 2009 and has worked closely with Schmidt and other fellow members to steward the institution in its mission of improving human health by advancing the understanding and treatment of disease.&
Permission granted by Incyte Dive Brief: Incyte has named veteran pharmaceutical executive Bill Meury as its new CEO, replacing longtime head Hervé Hoppenot, who led the cancer and blood disease drugmaker for the past 11 years. says US won’t donate to global vaccine effort View all Events 07 JUL Webinar | 10 a.m. billion in sales.
Rates of chronic disease are high, as is obesity. Referencing an interview with Kennedy from 2023, the Post says that his views on health “were a head-scratching spaghetti of what we can only call warped conspiracy theories, and not just on vaccines.” Kennedy’s tag line is that he and Trump will “Make America Healthy Again.”
Collaborative Surveillance Strengthening disease surveillance remains a central pillar of the response. Tailoring vaccination approaches to local epidemiology using strategies such as fractional dosing during supply shortages. Integrating vaccination efforts with surveillance and contact tracing operations.
The outcomes of this year’s two-day deliberations will directly feed into two pivotal events: the United Nations General Assembly’s fourth high-level meeting on noncommunicable diseases (NCDs) in September, and the G20 Health Ministers’ and Leaders’ Summits to be held in South Africa this November.
Importantly, it also provides a more holistic response to sexually transmitted infections (STIs) by strengthening detection, treatment, and prevention across multiple diseases at once. The disease has become the second leading cause of stillbirth globally, pointing to its broader implications for maternal and neonatal health.
Current Treatment Landscape and Therapeutic Approaches The management of Long COVID remains challenging due to its heterogeneous presentation, unclear pathophysiology, and the absence of approved disease-modifying therapies. Current approaches focus on symptom management, rehabilitation, and investigating potential underlying mechanisms.
The findings show zoonotic diseases began spreading around 6,500 years ago, likely triggered by farming and animal domestication. These ancient infections may still influence us today, and help guide the vaccines of tomorrow.
Importantly, a study assessing the effects of this medication on dogs’ ability to respond to vaccines demonstrated that NUMELVI had no measurable impact on their vaccine responses — a strong indicator that it maintains the functionality of the adaptive immune system while addressing disease symptoms. Source link
And some of the remedies are still practiced today: the treatment for Guinea-worm disease was, and still is , to wrap the emerging end of the worm around a stick and slowly pull it out. estimated to be about 29 million people) took daily aspirin to prevent cardiovascular disease. As a piece of history, it’s fantastic.
Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from News roundup Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules Biocryst is offloading part of its business to an Italian drugmaker for $250 million upfront.
Dr. Makary noted that he doesnt believe that the traditional playbook works for everythingparticularly in the case of life-threatening diseases where randomized controlled trials are neither feasible nor humane. He also specifically mentioned rare diseases here , in addition to his example of late-stage illnesses.
This announcement was made as part of their pledges to Gavi, the Vaccine Alliance, ahead of Gavi’s sixth replenishment cycle (Gavi 6.0) In a landmark move, Bharat Biotech will progressively reduce the price of the RTS,S vaccine to below $5 per dose by 2028—a reduction of more than 50%. scheduled for 2026 to 2030.
MONDAY, July 7, 2025 — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and Prevention (CDC). This marks a change from the.
These submissions spanned a wide range of health issues, from equitable vaccine access to financing for resilient health systems. The event marked a turning point for civil society’s formal inclusion in global health decision-making, a movement that has been gradually gaining momentum but found new institutional strength at WHA78.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content